BIOMAT Database Logo BIOMAT Database Logo

Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration. 2015

Wesley D Oliver, and Emily L Heil, and Jeffrey P Gonzales, and Shailly Mehrotra, and Kathryn Robinett, and Paul Saleeb, and David P Nicolau
University of Maryland Medical Center, Baltimore, Maryland, USA.

Extended-infusion ceftolozane-tazobactam treatment at 1.5 g every 8 h was used to treat multidrug-resistant Pseudomonas aeruginosa in a critically ill patient on continuous venovenous hemofiltration. Serum drug concentrations were measured at 1, 4, 5, 6, and 8 h after the start of infusion. Prefilter levels of ceftolozane produced a maximum concentration of drug (Cmax) of 38.57 μg/ml, concentration at the end of the dosing interval (Cmin) of 31.63 μg/ml, time to Cmax (Tmax) of 4 h, area under the concentration-time curve from 0 to 8 h (AUC0-8) of 284.38 μg · h/ml, and a half-life (t1/2) of 30.7 h. The concentrations were eight times the susceptibility breakpoint for the entire dosing interval.

UI MeSH Term Description Entries
D007362 Intensive Care Units Hospital units providing continuous surveillance and care to acutely ill patients. ICU Intensive Care Units,Intensive Care Unit,Unit, Intensive Care
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010397 Penicillanic Acid A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed) Acid, Penicillanic
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D006440 Hemofiltration Extracorporeal ULTRAFILTRATION technique without HEMODIALYSIS for treatment of fluid overload and electrolyte disturbances affecting renal, cardiac, or pulmonary function. Arteriovenous Hemofiltration,Venovenous Hemofiltration,Arteriovenous Hemofiltrations,Hemofiltration, Arteriovenous,Hemofiltration, Venovenous,Hemofiltrations,Venovenous Hemofiltrations

Related Publications

Wesley D Oliver, and Emily L Heil, and Jeffrey P Gonzales, and Shailly Mehrotra, and Kathryn Robinett, and Paul Saleeb, and David P Nicolau
Lacosamide Pharmacokinetics in a Critically Ill Patient Receiving Continuous Venovenous Hemofiltration.
February 2018, Pharmacotherapy,
Wesley D Oliver, and Emily L Heil, and Jeffrey P Gonzales, and Shailly Mehrotra, and Kathryn Robinett, and Paul Saleeb, and David P Nicolau
Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration.
April 2019, Critical care (London, England),
Wesley D Oliver, and Emily L Heil, and Jeffrey P Gonzales, and Shailly Mehrotra, and Kathryn Robinett, and Paul Saleeb, and David P Nicolau
Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration.
September 2014, Pharmacotherapy,
Wesley D Oliver, and Emily L Heil, and Jeffrey P Gonzales, and Shailly Mehrotra, and Kathryn Robinett, and Paul Saleeb, and David P Nicolau
Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients.
February 2002, Pharmacotherapy,
Wesley D Oliver, and Emily L Heil, and Jeffrey P Gonzales, and Shailly Mehrotra, and Kathryn Robinett, and Paul Saleeb, and David P Nicolau
Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
July 2017, Antimicrobial agents and chemotherapy,
Wesley D Oliver, and Emily L Heil, and Jeffrey P Gonzales, and Shailly Mehrotra, and Kathryn Robinett, and Paul Saleeb, and David P Nicolau
Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients.
April 2012, Journal of chemotherapy (Florence, Italy),
Wesley D Oliver, and Emily L Heil, and Jeffrey P Gonzales, and Shailly Mehrotra, and Kathryn Robinett, and Paul Saleeb, and David P Nicolau
Pharmacokinetics of zanamivir in critically ill patients undergoing continuous venovenous hemofiltration.
February 2023, Antiviral therapy,
Wesley D Oliver, and Emily L Heil, and Jeffrey P Gonzales, and Shailly Mehrotra, and Kathryn Robinett, and Paul Saleeb, and David P Nicolau
Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy.
May 2016, Pharmacotherapy,
Wesley D Oliver, and Emily L Heil, and Jeffrey P Gonzales, and Shailly Mehrotra, and Kathryn Robinett, and Paul Saleeb, and David P Nicolau
Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.
September 2016, International journal of antimicrobial agents,
Wesley D Oliver, and Emily L Heil, and Jeffrey P Gonzales, and Shailly Mehrotra, and Kathryn Robinett, and Paul Saleeb, and David P Nicolau
Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.
December 1997, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!